



Evoked Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference

September 4, 2024

SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Evoked Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that management will participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place from September 9 – 11, 2024 at the Lotte New York Palace Hotel in New York City.

Evoked's presentation covering the recent positive commercial progress with the Company's flagship product for diabetic gastroparesis treatment, Gimoti® will be available on demand to registered attendees via the conference platform **beginning Monday, September 9, 2024 at 7:00 a.m. ET**. An archived webcast of the presentation can also be found under the *events* section of Evoked Pharma's [investor relations website](#).

Management will also participate throughout the conference in one-on-one meetings and with investors in New York City.

About Evoked Pharma, Inc.

Evoked is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.

Visit www.EvokedPharma.com for more information.

Follow Evoked Pharma on [LinkedIn](#)

Follow Evoked Pharma on [Twitter](#)

Safe Harbor Statement

Evoked cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negatives of these terms or other similar expressions. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding: guidance regarding 2024 net product sales; potential future prescribing trends for GIMOTI based on Evoked's or EVERESANA's marketing efforts; Evoked's commercialization plans, the potential market opportunity for GIMOTI, Evoked's partnership with ASPN Pharmacies, growth in prescriptions, patients taking GIMOTI and the conversion of prescriptions to fills, and Evoked's expected cash runway. The inclusion of forward-looking statements should not be regarded as a representation by Evoked that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoked's business, including, without limitation: Evoked may not be able to achieve its guidance for 2024 including as a result of decreased demand for GIMOTI; Evoked's and EVERESANA's ability to successfully drive market demand for GIMOTI; Evoked's ability to obtain additional financing as needed to support its operations; Evoked may use its capital resources sooner than expected; warrant holders may choose not to exercise any of the outstanding warrants; Evoked's dependence on third parties for the manufacture of GIMOTI; Evoked is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoked's ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in Evoked's prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoked undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor & Media Contact:

Daniel Kontoh-Boateng

DKB Partners

Tel: 862-213-1398

dboateng@dkbpartners.net



Source: Evoke Pharma, Inc.